Illumina, Inc. (ILMN) SVP Oene Mark Van Sells 1,232 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 1,232 shares of Illumina stock in a transaction on Monday, November 13th. The shares were sold at an average price of $207.78, for a total value of $255,984.96. Following the completion of the transaction, the senior vice president now owns 11,691 shares of the company’s stock, valued at $2,429,155.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oene Mark Van also recently made the following trade(s):

  • On Wednesday, November 15th, Oene Mark Van sold 1,250 shares of Illumina stock. The shares were sold at an average price of $207.76, for a total value of $259,700.00.
  • On Thursday, October 12th, Oene Mark Van sold 1,250 shares of Illumina stock. The shares were sold at an average price of $207.21, for a total value of $259,012.50.
  • On Tuesday, September 12th, Oene Mark Van sold 9,729 shares of Illumina stock. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57.

Illumina, Inc. (ILMN) traded up $0.51 during midday trading on Friday, hitting $209.02. The stock had a trading volume of 545,558 shares, compared to its average volume of 959,780. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market cap of $30,440.00, a price-to-earnings ratio of 60.25, a PEG ratio of 3.40 and a beta of 0.74.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the previous year, the company posted $0.97 EPS. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. sell-side analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) SVP Oene Mark Van Sells 1,232 Shares of Stock” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/18/illumina-inc-ilmn-svp-oene-mark-van-sells-1232-shares-of-stock.html.

Large investors have recently made changes to their positions in the stock. Paradigm Asset Management Co. LLC increased its holdings in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the period. Patriot Financial Group Insurance Agency LLC increased its holdings in Illumina by 1.4% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after purchasing an additional 43 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in Illumina by 298.7% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock valued at $1,813,000 after purchasing an additional 7,827 shares during the period. Eagle Asset Management Inc. purchased a new position in Illumina during the 2nd quarter valued at about $27,175,000. Finally, Intellectus Partners LLC increased its holdings in Illumina by 6.6% during the 2nd quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock valued at $1,871,000 after purchasing an additional 664 shares during the period. Institutional investors own 92.70% of the company’s stock.

Several equities research analysts recently issued reports on the company. Wells Fargo & Company reissued a “market perform” rating and set a $205.00 price objective (up previously from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Barclays PLC reissued an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price objective for the company in a research note on Wednesday, August 2nd. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Canaccord Genuity reissued a “hold” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the company. Illumina has a consensus rating of “Hold” and an average target price of $200.88.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply